[go: up one dir, main page]

NO971247L - Defektive, rekombinante adenoviruser med inaktivt IVa2-gen - Google Patents

Defektive, rekombinante adenoviruser med inaktivt IVa2-gen

Info

Publication number
NO971247L
NO971247L NO971247A NO971247A NO971247L NO 971247 L NO971247 L NO 971247L NO 971247 A NO971247 A NO 971247A NO 971247 A NO971247 A NO 971247A NO 971247 L NO971247 L NO 971247L
Authority
NO
Norway
Prior art keywords
defective
inactive
recombinant adenoviruses
iva2 gene
gene
Prior art date
Application number
NO971247A
Other languages
English (en)
Other versions
NO319055B1 (no
NO971247D0 (no
Inventor
Cecile Orsini
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO971247L publication Critical patent/NO971247L/no
Publication of NO971247D0 publication Critical patent/NO971247D0/no
Publication of NO319055B1 publication Critical patent/NO319055B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19971247A 1994-09-27 1997-03-18 Defekte, rekombinante adenoviruser med inaktivt IVa2-gen NO319055B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9411511A FR2724945B1 (fr) 1994-09-27 1994-09-27 Vecteurs viraux et utilisation en therapie genique
PCT/FR1995/001228 WO1996010088A1 (fr) 1994-09-27 1995-09-22 ADENOVIRUS RECOMBINANTS DEFECTIFS AVEC UN GENE IVa2 INACTIVE

Publications (3)

Publication Number Publication Date
NO971247L true NO971247L (no) 1997-03-18
NO971247D0 NO971247D0 (no) 1997-03-18
NO319055B1 NO319055B1 (no) 2005-06-13

Family

ID=9467310

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971247A NO319055B1 (no) 1994-09-27 1997-03-18 Defekte, rekombinante adenoviruser med inaktivt IVa2-gen

Country Status (18)

Country Link
US (1) US6200798B1 (no)
EP (1) EP0783585B1 (no)
JP (1) JPH10506018A (no)
KR (1) KR100484441B1 (no)
AT (1) ATE331801T1 (no)
AU (1) AU712304B2 (no)
CA (1) CA2197904A1 (no)
DE (1) DE69535093T2 (no)
DK (1) DK0783585T3 (no)
ES (1) ES2268695T3 (no)
FI (1) FI971275L (no)
FR (1) FR2724945B1 (no)
IL (1) IL115432A (no)
MX (1) MX9701766A (no)
NO (1) NO319055B1 (no)
PT (1) PT783585E (no)
WO (1) WO1996010088A1 (no)
ZA (1) ZA958128B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6816194A (en) * 1993-04-20 1994-11-08 Robinson, William S. Methods and materials for treatment of individuals infected with intracellular infectious agents
AU709498B2 (en) * 1994-12-12 1999-09-02 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
CA2308017A1 (en) 1997-10-30 1999-05-14 Erik S. Falck-Pedersen A method of inhibiting an immune response to a recombinant vector
CA2340276A1 (en) 1998-08-28 2000-03-09 Duke University Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
WO2004018627A2 (en) * 2002-08-22 2004-03-04 Merck & Co., Inc. Methods for propagating adenovirus and virus produced thereby
SI2002003T1 (sl) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.

Also Published As

Publication number Publication date
DE69535093T2 (de) 2007-01-04
ES2268695T3 (es) 2007-03-16
IL115432A (en) 2006-10-05
JPH10506018A (ja) 1998-06-16
FR2724945A1 (fr) 1996-03-29
IL115432A0 (en) 1996-01-31
AU712304B2 (en) 1999-11-04
EP0783585B1 (fr) 2006-06-28
FR2724945B1 (fr) 1996-12-27
ATE331801T1 (de) 2006-07-15
ZA958128B (en) 1996-04-24
EP0783585A1 (fr) 1997-07-16
FI971275A0 (fi) 1997-03-26
AU3525095A (en) 1996-04-19
KR970706397A (ko) 1997-11-03
DK0783585T3 (da) 2006-10-23
NO319055B1 (no) 2005-06-13
NO971247D0 (no) 1997-03-18
MX9701766A (es) 1997-06-28
DE69535093D1 (de) 2006-08-10
US6200798B1 (en) 2001-03-13
WO1996010088A1 (fr) 1996-04-04
KR100484441B1 (ko) 2006-01-27
CA2197904A1 (fr) 1996-04-04
PT783585E (pt) 2006-11-30
FI971275L (fi) 1997-03-26

Similar Documents

Publication Publication Date Title
MX9603002A (es) Procedimiento para la preparacion de virus asociados a los adenovirus (aav), recombinantes, y usos de los mismos.
IL110284A0 (en) Viral vectors and their use in gene therapy
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
KR970706806A (ko) 신규한 아데노바이러스성 벡터, 패키징 세포주, 재조합 아데노바이러스와 그 방법(novel adenoviral vectors, packagning cell lines, recombinant adenoviruses and methods)
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
ES2191663T3 (es) Virus recombinante de la viruela porcina.
NO20024157L (no) Kasein-avledete peptider og anvendelser derav i terapi
NO971247D0 (no) Defektive, rekombinante adenoviruser med inaktivt IVa2-gen
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
BR9607583B1 (pt) plasmìdios procarióticos recombinantes.
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
NO974179D0 (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
MX9702078A (es) Adenovirus que comprenden dos genes terapeuticos: suicida e inmunoestimulante.
FR2717496B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2475337A1 (en) Methods for cultivating cells and propagating viruses
FR2720756B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2717497B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2718749B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
FR2726575B1 (fr) Virus recombinants, preparation et utilisation en therapie genique